A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
Background: Novel therapies for multiple myeloma (MM) promise to improve outcomes but are also associated with substantial increasing costs. Evidence regarding cost-effectiveness of novel treatments is necessary, but a comprehensive up-to-date overview of the cost-effectiveness evidence of novel tre...
Guardado en:
Autores principales: | Maarten R. Seefat, David G. J. Cucchi, Stijn Dirven, Kaz Groen, Sonja Zweegman, Hedwig M. Blommestein |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3e3da36cf816463da7d0e086f3846c0e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani D, et al.
Publicado: (2017) -
New developments in the treatment of multiple myeloma – clinical utility of daratumumab
por: McEllistrim C, et al.
Publicado: (2017) -
Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Shansa Pranami E. Jayaweera, et al.
Publicado: (2021) -
Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
por: Edvan de Queiroz Crusoé, et al.
Publicado: (2021) -
Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: Shebli ATRASH, et al.
Publicado: (2021)